We have located links that may give you full text access.
New horizons in ambulatory electroencephalography.
Since its inception 30 years ago, AEEG has continued to evolve--from four-channel tape recorders to 32-channel digital recorders with sophisticated automatic spike and seizure detection algorithms. AEEG remains an important tool in epilepsy evaluation. In the near future, smaller, faster, and more sophisticated AEEGs will be developed. Seizure detection/anticipation systems will allow the wearer to be forewarned of a seizure so that appropriate safety measures can be taken. With further refinement in our understanding of nonlinear dynamic analysis to define the pre-ictal state, AEEG will be coupled with an accurate seizure anticipation device in a closed-loop system, providing a time window during which therapeutic intervention can occur, to prevent a seizure. The therapeutic intervention will most likely involve vagus nerve or deep brain stimulation. An alternative is that the patient may learn to recognize early symptoms of the pre-ictal state and use behavioral biofeedback interventions to avoid a clinical seizure. In order to achieve convenient ambulatory recording and seizure detection that could realistically improve the lives of patients with refractory epilepsy, the process of miniaturization of such a device to a convenient size must be accomplished. One of the aspects of epilepsy that patients find most frustrating, and that most limits activities, is the vulnerability to sudden unexpected incapacitation due to the occurrence of a seizure. With miniaturization of AEEG and seizure anticipation technology, and advancements in our ability to identify the transition from pre-ictal to ictal state, there is realistic hope that patients with refractory epilepsy may gain control over their seizures and enjoy significantly improved quality of life.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app